---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-051047"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2024-12-20T23:59:59+00:00"
generated_at: "2026-05-29T00:07:24.470220+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix stockholders approve 2024 Long-Term Incentive Plan and elect eight directors at annual meeting.

## Summary
- Stockholders approved 2024 Long-Term Incentive Plan with 635,057 for, 262,753 against, 2,012 abstentions, and 1,146,998 broker non-votes.
- Eight directors elected: Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, Harold Jacob, Thomas Mika, Brian Murphy, Maria Schroeder, each receiving 668,461–685,652 for votes.
- Ratification of Zwik CPA as auditor for FY2024 passed with 2,006,926 for, 25,623 against, 14,271 abstentions.
- Advisory vote on executive compensation approved: 629,513 for, 265,874 against, 4,435 abstentions, 1,146,998 broker non-votes.
- Adjournment proposal approved (1,656,819 for, 376,540 against) but not needed as meeting proceeded.

## SEC filing metadata
- accession: 0001493152-24-051047
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2024-12-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315224051047/0001493152-24-051047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315224051047/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-051047
- JSON: https://secwatch.observer/filing/0001493152-24-051047.json
- Plain text: https://secwatch.observer/filing/0001493152-24-051047.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.